Save
ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS
ESGO eAcademy, Frederic Amant, 202790
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
ESGO eAcademy, Sarah Blagden, 202788
CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
ESGO eAcademy, Charlie Gourley, 202787
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
ESGO eAcademy, Willemien van Driel, 202786
ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
ESGO eAcademy, Jonathan Ledermann, 202785
RANKL -BONES, SEX, AND BREAST CANCER
ESGO eAcademy, Josef Penninger, 202794
WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
ESGO eAcademy, Christian Marth, 202795
Discussion and Closing
ESGO eAcademy, Sandro Pignata, 202898
Future therapies
ESGO eAcademy, Kathleen Moore, 202897
Adjuvant management
ESGO eAcademy, Nicoletta Colombo, 202896
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, Sandro Pignata, 202766
ESGO – A STORY OF SUCCESS
ESGO eAcademy, David Cibula, 202757
INTRODUCTION
ESGO eAcademy, Luis M. Chiva, 202756
LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.
ESGO eAcademy, Domenica Lorusso, 202722
WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?
ESGO eAcademy, Isabel Carriles, 202721
PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL
ESGO eAcademy, Sarah Kitson, 202719
Closing and remarcs
ESGO eAcademy, Andreas Du Bois, 202716
Being Practical Case 3
ESGO eAcademy, Christian Marth, 202715
Being Practical Case 2
ESGO eAcademy, Nicoletta Colombo, 202714
Being Practical Case 1
ESGO eAcademy, Isabelle Ray-Coquard, 202713
SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
ESGO eAcademy, Felix Hilpert, 202712
Introduction
ESGO eAcademy, Andreas Du Bois, 202711
CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.
ESGO eAcademy, Ilary Ruscito, 202699
CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)
ESGO eAcademy, Umesh Mahantshetty, 202698
AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS
ESGO eAcademy, Isabelle Ray-Coquard, 202697
EMBRACE THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202696
Long- term therapy with gonadoliberin analogues in patient with ovarian cancer.
ESGO eAcademy, Session Speakers, 191006
High grade serous ovarian cancer stage IV, multiple relapses
ESGO eAcademy, Session Speakers, 191003
Ovarian Cancer in Pregnancy
ESGO eAcademy, Session Speakers, 190595
Surgical treatment of low grade serous ovarian cancer
ESGO eAcademy, Jalid Sehouli, 180471
Medical Tumor Therapy for Germ Cell Tumors of Adults
ESGO eAcademy, Michael Seckl, 180466
Systemic treatment for low grade serous carcinoma
ESGO eAcademy, Michael Seckl, 180469
Surgical treatment for malignant germ cell tumor.
ESGO eAcademy, Pauline Wimberger, 180467
Pathologic aspects of Germ Cell Tumors
ESGO eAcademy, Doris Mayr, 180468
Pathologic aspects of Low Grade Serous Ovarian Cancer
ESGO eAcademy, Doris Mayr, 180470
Look into the future: Medical treatment of ovarian cancer in 2026
ESGO eAcademy, Ignace B. Vergote, 173572
Immunotherapy in gynecological malignancies
ESGO eAcademy, An Coosemans, 173570
Why do studies of targeted treatment fail?
ESGO eAcademy, Jonathan Ledermann, 173568
Targeting PARP: Mechanisms of action, available evidence, selection of patients, management of toxicities
ESGO eAcademy, Jonathan Ledermann, 173567
Targeting tyrosine kinases
ESGO eAcademy, Jonathan Ledermann, 173566
Molecular pathways in cervical cancer
ESGO eAcademy, Heidi Lyng, 173565
Molecular pathways in endometrial cancer
ESGO eAcademy, Henrica Maria Johanna Werner, 173564
Molecular pathways of low-grade ovarian cancer
ESGO eAcademy, Kristina Lindemann, 173563
Molecular pathways of high grade ovarian cancer
ESGO eAcademy, Adriaan Vanderstichele, 173562
Uterine sarcoma study
ESGO eAcademy, Frederic Amant, 173560
Ultrasound guided procedures
ESGO eAcademy, Michal Zikan, 173920
Ovarian cancer staging
ESGO eAcademy, Daniela Fischerova, 173919
Endometrial cancer diagnosis and staging
ESGO eAcademy, Elisabeth Epstein, 173918
Cervical cancer staging
ESGO eAcademy, Antonia Testa, 173917
Abdominal scan
ESGO eAcademy, Daniela Fischerova, 173916
Pelvic imaging
ESGO eAcademy, Daniela Fischerova, 173915
Introduction
ESGO eAcademy, David Cibula, 173914
PMMR in endometrial cancer - Part one - Compartmental lymphatic network of uterine corpus and its drainage
ESGO eAcademy, Rainer Kimmig, 166631
PMMR in endometrial cancer - Part two - Surgical technique
ESGO eAcademy, Rainer Kimmig, 166632
Highlights about Radiation Oncology in Cervical Cancer
ESGO eAcademy, Richard Poetter, 150847
Adjuvant Treatment and Place of Radiation Therapy in Vulvar Cancer
ESGO eAcademy, Carien Creutzberg, 150846
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
ESGO eAcademy, Mansoor Raza Mirza, 154789
New ESGO Guidelines of Management of Vulvar Cancer
ESGO eAcademy, Ate van der Zee, 150845
How to Stage Locally Advanced Cervical Cancer (Radiological and Surgical) before Chemoradiation Therapy
ESGO eAcademy, Sebastien Gouy, 150844
Management of the Clear Cell Ovarian Carcinoma
ESGO eAcademy, Keiichi Fujiwara, 150843
Phase 2: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Jonathan Ledermann, 150268
Surrogate Endpoints
ESGO eAcademy, Paolo Bruzzi, 150266
Phase 1/1B: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Cristiana Sessa, 150267
Statistical Plans, Interim Analysis and Subgroup Analysis
ESGO eAcademy, Paolo Bruzzi, 150265
Vulvar Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Fabio Landoni, 150264
Endometrial Cancer: What Do We Know? What Don't We Know ? What Should Be Investigated?
ESGO eAcademy, Eric Pujade-Lauraine, 150263
Uterine Sarcoma: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Andres Poveda, 150262
Cervical Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Christian Marth, 150261
Welcome & Introduction
ESGO eAcademy, Nicoletta Colombo, 150269
New Classification of Uterine Sarcoma
ESGO eAcademy, Sabrina Croce, 147380
Gastric-type Mucinous Cervical Adenocarcinoma
ESGO eAcademy, Mojgan Devouassoux-Shisheboran, 148332
Vulvovaginal Glandular Neoplasia
ESGO eAcademy, Mojgan Devouassoux-Shisheboran, 148333
Pathology of Clear Cell Ovarian Tumors
ESGO eAcademy, Ester Oliva, 147379
New Classification and Molecular of Endometrial Cancers
ESGO eAcademy, Sigurd Lax, 147381
Pathologic Characteristics of Mucinous Tumors (Borderline and Invasive: Infltrative/expansile Subtypes)
ESGO eAcademy, Sigurd Lax, 147383
Aortic Extraperitoneal Lymphadenectomy
ESGO eAcademy, Lucas Minig, 148602
Peritoneal Suture During Extraperitoneal Lymphadenectomy
ESGO eAcademy, Lucas Minig, 148603
Sentinel Node Detection
ESGO eAcademy, Lucas Minig, 148604
Dissection of the Avascular Spaces of the Pelvis
ESGO eAcademy, Lucas Minig, 148605
Pelvic Lymphadenectomy
ESGO eAcademy, Lucas Minig, 148606
Radical Oophorectomy with Colorectal Resection for Advanced Ovarian Cancer
ESGO eAcademy, Lucas Minig, 148607
Ileo-Colic Resection with Anastomosis for Advanced Ovarian Cancer
ESGO eAcademy, Lucas Minig, 148608
Pathological and Molecular Classification of Epithelial Ovarian Cancer
ESGO eAcademy, Sigurd Lax, 147382
Restoring the Function of Mutated P53 - a Major Contribution to Carcinogenesis
ESGO eAcademy, John A Green, 147116
Genetic Testing in Ovarian Cancer Patients: How Far Should We Go
ESGO eAcademy, Charlie Gourley, 147115
Adjuvant Therapeutic Approaches by Histological Subtype with Implications for Treatment
ESGO eAcademy, Jonathan Ledermann, 147114
Prophylactic Surgery in High Risk Population
ESGO eAcademy, Christina Fotopoulou, 147112
Laser Skinning Vulvectomy
ESGO eAcademy, Michael G. Halaska, 147110
LEEP/LLETZ and Needle Conization
ESGO eAcademy, Ilker Selcuk, 147109
Cold Knife Conization and Sturmdorf Technique
ESGO eAcademy, Ignacio Zapardiel Gultierrez, 147108
Simple Solutions for Developing Countries for Breast Cancer Screening
ESGO eAcademy, Murat Gultekin, 147106
Current Situation of Breast Cancer Screening Startegies in Europe and Around the World
ESGO eAcademy, Larry von Karsa, 147105
Evaluation of Mammography for the Detection of Breast Cancer in Screening Programs
ESGO eAcademy, Peter Dean, 147104
Molecular Cancer Genetics
ESGO eAcademy, Henrica Maria Johanna Werner, 147103
Endometrial Cancers Prevention and Screening Methods
ESGO eAcademy, Thierry A.M. Van Den Bosch, 147102
Chemoprevention of Endometrial Cancers
ESGO eAcademy, Pauline Wimberger, 147100
Obesity and Gynaecological Cancers
ESGO eAcademy, Maria Kyrgiou, 147099
Follow-up and Treatment of Recurrences
ESGO eAcademy, Vesna Kesic, 147098
Should CIN2 Lesions Be Treated and When?
ESGO eAcademy, Maria Kyrgiou, 147097
Screening after Vaccination
ESGO eAcademy, Jack Cuzick, 147096